APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Medications for Multiple Sclerosis

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oral Medications for Multiple Sclerosis Industry Growth and Trends Forecast to 2032

Report ID 174019970127 December 2025121 pages

Choose your research edition.

Industry ResearchOral Medications for Multiple Sclerosis Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Medications for Multiple Sclerosis Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oral Medications for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Medications for Multiple Sclerosis Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Medications for Multiple Sclerosis Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Oral Medications for Multiple Sclerosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Medications for Multiple Sclerosis include Sichuan Omnis Pharmaceutical, CGeneTech (Suzhou, China), Qilu Pharmaceutical, Nanjing Healthnice Pharmaceutical, HEC Pharm, Cisen Pharmaceutical, Zydus, Viatris and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oral Medications for Multiple Sclerosis market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oral Medications for Multiple Sclerosis market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oral Medications for Multiple Sclerosis market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oral Medications for Multiple Sclerosis.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Oral Medications for Multiple Sclerosis market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oral Medications for Multiple Sclerosis Market by Company

Sichuan Omnis Pharmaceutical

CGeneTech (Suzhou, China)

Qilu Pharmaceutical

Nanjing Healthnice Pharmaceutical

HEC Pharm

Cisen Pharmaceutical

Zydus

Viatris

Teva

Sun Pharmaceuticals

Sanofi

Sandoz

Novartis

Mylan

Merck

Janssen

Glenmark Pharmaceuticals

Dr. Reddy's Laboratories

Bristol Myers Squibb

Biogen

Banner Life Sciences

Apotex

Alembic

Accord Healthcare

Oral Medications for Multiple Sclerosis Segment by Type

Ozanimod

Ponesimod

Fingolimod

Diroximel Fumarate

Monomethyl Fumarate

Dimethyl Fumarate

Cladribine

Teriflunomide

Siponimod

Oral Medications for Multiple Sclerosis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Oral Medications for Multiple Sclerosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Medications for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Medications for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Medications for Multiple Sclerosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Medications for Multiple Sclerosis manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Oral Medications for Multiple Sclerosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ozanimod Table 2. Major Company of Ponesimod Table 3. Major Company of Fingolimod Table 4. Major Company of Diroximel Fumarate Table 5. Major Company of Monomethyl Fumarate Table 6. Major Company of Dimethyl Fumarate Table 7. Major Company of Cladribine Table 8. Major Company of Teriflunomide Table 9. Major Company of Siponimod Table 10. Global Oral Medications for Multiple Sclerosis Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 11. Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 12. Global Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Type (2021-2026) Table 13. Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (US$ Million) Table 14. Global Oral Medications for Multiple Sclerosis Sales Market Share in Value by Type (2021-2026) Table 15. Global Oral Medications for Multiple Sclerosis Price by Type (2021-2026) & (US$/Unit) Table 16. Global Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 17. Global Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Type (2027-2032) Table 18. Global Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (US$ Million) Table 19. Global Oral Medications for Multiple Sclerosis Sales Market Share in Value by Type (2027-2032) Table 20. Global Oral Medications for Multiple Sclerosis Price by Type (2027-2032) & (US$/Unit) Table 21. North America Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 22. North America Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (US$ Million) Table 23. Europe Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 24. Europe Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (US$ Million) Table 25. Asia-Pacific Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 26. Asia-Pacific Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (US$ Million) Table 27. Latin America Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 28. Latin America Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (US$ Million) Table 29. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 30. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (US$ Million) Table 31. Oral Medications for Multiple Sclerosis Industry Trends Table 32. Oral Medications for Multiple Sclerosis Industry Drivers Table 33. Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges Table 34. Oral Medications for Multiple Sclerosis Industry Restraints Table 35. Global Oral Medications for Multiple Sclerosis Sales Revenue by Company (US$ Million) & (2021-2026) Table 36. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Company (2021-2026) Table 37. Global Oral Medications for Multiple Sclerosis Sales by Company (2021-2026) & (K Units) Table 38. Global Oral Medications for Multiple Sclerosis Sales Share by Company (2021-2026) Table 39. Global Oral Medications for Multiple Sclerosis Market Price by Company (2021-2026) & (US$/Unit) Table 40. Global Oral Medications for Multiple Sclerosis Industry Company Ranking, 2024 VS 2025 VS 2026 Table 41. Global Oral Medications for Multiple Sclerosis Major Company Production Sites and Headquarters Table 42. Global Oral Medications for Multiple Sclerosis Company, Product Type & Application Table 43. Global Oral Medications for Multiple Sclerosis Company Establishment Date Table 44. Global Company Market Concentration Ratio (CR5 and HHI) Table 45. Global Oral Medications for Multiple Sclerosis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 46. Global Oral Medications for Multiple Sclerosis Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 47. Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2026) & (K Units) Table 48. Global Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Region (2021-2026) Table 49. Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2026) & (US$ Million) Table 50. Global Oral Medications for Multiple Sclerosis Sales Market Share in Value by Region (2021-2026) Table 51. Global Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 52. Global Oral Medications for Multiple Sclerosis Sales by Region (2027-2032) & (K Units) Table 53. Global Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Region (2027-2032) Table 54. Global Oral Medications for Multiple Sclerosis Sales by Region (2027-2032) & (US$ Million) Table 55. Global Oral Medications for Multiple Sclerosis Sales Market Share in Value by Region (2027-2032) Table 56. Global Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 57. Global Oral Medications for Multiple Sclerosis Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 58. Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 59. Global Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Application (2021-2026) Table 60. Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (US$ Million) Table 61. Global Oral Medications for Multiple Sclerosis Sales Market Share in Value by Application (2021-2026) Table 62. Global Oral Medications for Multiple Sclerosis Price by Application (2021-2026) & (US$/Unit) Table 63. Global Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 64. Global Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Application (2027-2032) Table 65. Global Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (US$ Million) Table 66. Global Oral Medications for Multiple Sclerosis Sales Market Share in Value by Application (2027-2032) Table 67. Global Oral Medications for Multiple Sclerosis Price by Application (2027-2032) & (US$/Unit) Table 68. North America Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 69. North America Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (US$ Million) Table 70. Europe Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 71. Europe Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (US$ Million) Table 72. Asia-Pacific Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 73. Asia-Pacific Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (US$ Million) Table 74. Latin America Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 75. Latin America Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (US$ Million) Table 76. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 77. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (US$ Million) Table 78. Sichuan Omnis Pharmaceutical Company Information Table 79. Sichuan Omnis Pharmaceutical Business Overview Table 80. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 82. Sichuan Omnis Pharmaceutical Recent Development Table 83. CGeneTech (Suzhou, China) Company Information Table 84. CGeneTech (Suzhou, China) Business Overview Table 85. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio Table 87. CGeneTech (Suzhou, China) Recent Development Table 88. Qilu Pharmaceutical Company Information Table 89. Qilu Pharmaceutical Business Overview Table 90. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 92. Qilu Pharmaceutical Recent Development Table 93. Nanjing Healthnice Pharmaceutical Company Information Table 94. Nanjing Healthnice Pharmaceutical Business Overview Table 95. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 97. Nanjing Healthnice Pharmaceutical Recent Development Table 98. HEC Pharm Company Information Table 99. HEC Pharm Business Overview Table 100. HEC Pharm Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio Table 102. HEC Pharm Recent Development Table 103. Cisen Pharmaceutical Company Information Table 104. Cisen Pharmaceutical Business Overview Table 105. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 107. Cisen Pharmaceutical Recent Development Table 108. Zydus Company Information Table 109. Zydus Business Overview Table 110. Zydus Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Zydus Oral Medications for Multiple Sclerosis Product Portfolio Table 112. Zydus Recent Development Table 113. Viatris Company Information Table 114. Viatris Business Overview Table 115. Viatris Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Viatris Oral Medications for Multiple Sclerosis Product Portfolio Table 117. Viatris Recent Development Table 118. Teva Company Information Table 119. Teva Business Overview Table 120. Teva Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Teva Oral Medications for Multiple Sclerosis Product Portfolio Table 122. Teva Recent Development Table 123. Sun Pharmaceuticals Company Information Table 124. Sun Pharmaceuticals Business Overview Table 125. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 127. Sun Pharmaceuticals Recent Development Table 128. Sanofi Company Information Table 129. Sanofi Business Overview Table 130. Sanofi Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Sanofi Oral Medications for Multiple Sclerosis Product Portfolio Table 132. Sanofi Recent Development Table 133. Sandoz Company Information Table 134. Sandoz Business Overview Table 135. Sandoz Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Sandoz Oral Medications for Multiple Sclerosis Product Portfolio Table 137. Sandoz Recent Development Table 138. Novartis Company Information Table 139. Novartis Business Overview Table 140. Novartis Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Novartis Oral Medications for Multiple Sclerosis Product Portfolio Table 142. Novartis Recent Development Table 143. Mylan Company Information Table 144. Mylan Business Overview Table 145. Mylan Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Mylan Oral Medications for Multiple Sclerosis Product Portfolio Table 147. Mylan Recent Development Table 148. Merck Company Information Table 149. Merck Business Overview Table 150. Merck Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Merck Oral Medications for Multiple Sclerosis Product Portfolio Table 152. Merck Recent Development Table 153. Janssen Company Information Table 154. Janssen Business Overview Table 155. Janssen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Janssen Oral Medications for Multiple Sclerosis Product Portfolio Table 157. Janssen Recent Development Table 158. Glenmark Pharmaceuticals Company Information Table 159. Glenmark Pharmaceuticals Business Overview Table 160. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 162. Glenmark Pharmaceuticals Recent Development Table 163. Dr. Reddy's Laboratories Company Information Table 164. Dr. Reddy's Laboratories Business Overview Table 165. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio Table 167. Dr. Reddy's Laboratories Recent Development Table 168. Bristol Myers Squibb Company Information Table 169. Bristol Myers Squibb Business Overview Table 170. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio Table 172. Bristol Myers Squibb Recent Development Table 173. Biogen Company Information Table 174. Biogen Business Overview Table 175. Biogen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. Biogen Oral Medications for Multiple Sclerosis Product Portfolio Table 177. Biogen Recent Development Table 178. Banner Life Sciences Company Information Table 179. Banner Life Sciences Business Overview Table 180. Banner Life Sciences Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio Table 182. Banner Life Sciences Recent Development Table 183. Apotex Company Information Table 184. Apotex Business Overview Table 185. Apotex Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 186. Apotex Oral Medications for Multiple Sclerosis Product Portfolio Table 187. Apotex Recent Development Table 188. Alembic Company Information Table 189. Alembic Business Overview Table 190. Alembic Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 191. Alembic Oral Medications for Multiple Sclerosis Product Portfolio Table 192. Alembic Recent Development Table 193. Accord Healthcare Company Information Table 194. Accord Healthcare Business Overview Table 195. Accord Healthcare Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 196. Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio Table 197. Accord Healthcare Recent Development Table 198. North America Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 199. North America Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 200. North America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2026) Table 201. North America Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032) & (K Units) Table 202. North America Oral Medications for Multiple Sclerosis Sales Market Share Forecast by Country (2027-2032) Table 203. North America Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 204. North America Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026) & (US$ Million) Table 205. North America Oral Medications for Multiple Sclerosis Market Share by Country (2021-2026) Table 206. North America Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 207. North America Oral Medications for Multiple Sclerosis Market Share Forecast by Country (2027-2032) Table 208. Europe Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 209. Europe Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 210. Europe Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2026) Table 211. Europe Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032) & (K Units) Table 212. Europe Oral Medications for Multiple Sclerosis Sales Market Share Forecast by Country (2027-2032) Table 213. Europe Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 214. Europe Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026) & (US$ Million) Table 215. Europe Oral Medications for Multiple Sclerosis Market Share by Country (2021-2026) Table 216. Europe Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 217. Europe Oral Medications for Multiple Sclerosis Market Share Forecast by Country (2027-2032) Table 218. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 219. Asia-Pacific Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 220. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2026) Table 221. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032) & (K Units) Table 222. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Market Share Forecast by Country (2027-2032) Table 223. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 224. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026) & (US$ Million) Table 225. Asia-Pacific Oral Medications for Multiple Sclerosis Market Share by Country (2021-2026) Table 226. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 227. Asia-Pacific Oral Medications for Multiple Sclerosis Market Share Forecast by Country (2027-2032) Table 228. Latin America Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 229. Latin America Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 230. Latin America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2026) Table 231. Latin America Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032) & (K Units) Table 232. Latin America Oral Medications for Multiple Sclerosis Sales Market Share Forecast by Country (2027-2032) Table 233. Latin America Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 234. Latin America Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026) & (US$ Million) Table 235. Latin America Oral Medications for Multiple Sclerosis Market Share by Country (2021-2026) Table 236. Latin America Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 237. Latin America Oral Medications for Multiple Sclerosis Market Share Forecast by Country (2027-2032) Table 238. Middle East and Africa Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 239. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 240. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2026) Table 241. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032) & (K Units) Table 242. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share Forecast by Country (2027-2032) Table 243. Middle East and Africa Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 244. Middle East and Africa Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026) & (US$ Million) Table 245. Middle East and Africa Oral Medications for Multiple Sclerosis Market Share by Country (2021-2026) Table 246. Middle East and Africa Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 247. Middle East and Africa Oral Medications for Multiple Sclerosis Market Share Forecast by Country (2027-2032) Table 248. Key Raw Materials Table 249. Raw Materials Key Suppliers Table 250. Oral Medications for Multiple Sclerosis Distributors List Table 251. Oral Medications for Multiple Sclerosis Customers List Table 252. Research Programs/Design for This Report Table 253. Authors List of This Report Table 254. Secondary Sources Table 255. Primary Sources List of Figures Figure 1. Oral Medications for Multiple Sclerosis Image Figure 2. Global Oral Medications for Multiple Sclerosis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Medications for Multiple Sclerosis Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Medications for Multiple Sclerosis Sales (2021-2032) & (K Units) Figure 5. Ozanimod Image Figure 6. Global Ozanimod Sales YoY Growth (2021-2032) & (K Units) Figure 7. Ponesimod Image Figure 8. Global Ponesimod Sales YoY Growth (2021-2032) & (K Units) Figure 9. Fingolimod Image Figure 10. Global Fingolimod Sales YoY Growth (2021-2032) & (K Units) Figure 11. Diroximel Fumarate Image Figure 12. Global Diroximel Fumarate Sales YoY Growth (2021-2032) & (K Units) Figure 13. Monomethyl Fumarate Image Figure 14. Global Monomethyl Fumarate Sales YoY Growth (2021-2032) & (K Units) Figure 15. Dimethyl Fumarate Image Figure 16. Global Dimethyl Fumarate Sales YoY Growth (2021-2032) & (K Units) Figure 17. Cladribine Image Figure 18. Global Cladribine Sales YoY Growth (2021-2032) & (K Units) Figure 19. Teriflunomide Image Figure 20. Global Teriflunomide Sales YoY Growth (2021-2032) & (K Units) Figure 21. Siponimod Image Figure 22. Global Siponimod Sales YoY Growth (2021-2032) & (K Units) Figure 23. Global Oral Medications for Multiple Sclerosis Market Size Overview by Type (2021-2032) & (US$ Million) Figure 24. Global Oral Medications for Multiple Sclerosis Market Share by Type 2025 VS 2032 Figure 25. North America Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Type in 2025 Figure 26. North America Oral Medications for Multiple Sclerosis Sales Market Share in Value by Type in 2025 Figure 27. Europe Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Type in 2025 Figure 28. Europe Oral Medications for Multiple Sclerosis Sales Market Share in Value by Type in 2025 Figure 29. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Type in 2025 Figure 30. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Market Share in Value by Type in 2025 Figure 31. Latin America Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Type in 2025 Figure 32. Latin America Oral Medications for Multiple Sclerosis Sales Market Share in Value by Type in 2025 Figure 33. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Type in 2025 Figure 34. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share in Value by Type in 2025 Figure 35. Global Top 5 and 10 Oral Medications for Multiple Sclerosis Players Market Share by Revenue in 2025 Figure 36. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 37. Hospital and Clinic Image Figure 38. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 39. Retail Pharmacies Image Figure 40. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 41. Other Image Figure 42. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 43. Global Oral Medications for Multiple Sclerosis Market Size Overview by Application (2021-2032) & (US$ Million) Figure 44. Global Oral Medications for Multiple Sclerosis Market Share by Application 2025 VS 2032 Figure 45. North America Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Application in 2025 Figure 46. North America Oral Medications for Multiple Sclerosis Sales Market Share in Value by Application in 2025 Figure 47. Europe Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Application in 2025 Figure 48. Europe Oral Medications for Multiple Sclerosis Sales Market Share in Value by Application in 2025 Figure 49. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Application in 2025 Figure 50. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Market Share in Value by Application in 2025 Figure 51. Latin America Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Application in 2025 Figure 52. Latin America Oral Medications for Multiple Sclerosis Sales Market Share in Value by Application in 2025 Figure 53. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share in Volume by Application in 2025 Figure 54. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share in Value by Application in 2025 Figure 55. North America Oral Medications for Multiple Sclerosis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. North America Oral Medications for Multiple Sclerosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. North America Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. North America Oral Medications for Multiple Sclerosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Oral Medications for Multiple Sclerosis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Europe Oral Medications for Multiple Sclerosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Europe Oral Medications for Multiple Sclerosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Oral Medications for Multiple Sclerosis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Asia-Pacific Oral Medications for Multiple Sclerosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America Oral Medications for Multiple Sclerosis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Latin America Oral Medications for Multiple Sclerosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Latin America Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Latin America Oral Medications for Multiple Sclerosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 72. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 73. Middle East and Africa Oral Medications for Multiple Sclerosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 74. Middle East and Africa Oral Medications for Multiple Sclerosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 75. Oral Medications for Multiple Sclerosis Value Chain Figure 76. Key Raw Materials Price Figure 77. Manufacturing Cost Structure Figure 78. Oral Medications for Multiple Sclerosis Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Years Considered Figure 82. Research Process Figure 83. Key Executives Interviewed

Scope & coverage.

Types
  • Ozanimod
  • Ponesimod
  • Fingolimod
  • Diroximel Fumarate
  • Monomethyl Fumarate
  • Dimethyl Fumarate
  • Cladribine
  • Teriflunomide
  • Siponimod
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Sichuan Omnis Pharmaceutical
  • CGeneTech (Suzhou, China)
  • Qilu Pharmaceutical
  • Nanjing Healthnice Pharmaceutical
  • HEC Pharm
  • Cisen Pharmaceutical
  • Zydus
  • Viatris
  • Teva
  • Sun Pharmaceuticals
  • Sanofi
  • Sandoz
  • Novartis
  • Mylan
  • Merck
  • Janssen
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Bristol Myers Squibb
  • Biogen
  • Banner Life Sciences
  • Apotex
  • Alembic
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Medications for Multiple Sclerosis Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Oral Medications for Multiple Sclerosis Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Oral Medications for Multiple Sclerosis Market by Type
  6. 1.3.1 Ozanimod
  7. 1.3.2 Ponesimod
  8. 1.3.3 Fingolimod
  9. 1.3.4 Diroximel Fumarate
  10. 1.3.5 Monomethyl Fumarate
  11. 1.3.6 Dimethyl Fumarate
  12. 1.3.7 Cladribine
  13. 1.3.8 Teriflunomide
  14. 1.3.9 Siponimod
  15. 1.4 Global Oral Medications for Multiple Sclerosis Market Size by Type
  16. 1.4.1 Global Oral Medications for Multiple Sclerosis Market Size Overview by Type (2021-2032)
  17. 1.4.2 Global Oral Medications for Multiple Sclerosis Historic Market Size Review by Type (2021-2026)
  18. 1.4.3 Global Oral Medications for Multiple Sclerosis Forecasted Market Size by Type (2027-2032)
  19. 1.5 Key Regions Market Size by Type
  20. 1.5.1 North America Oral Medications for Multiple Sclerosis Sales Breakdown by Type (2021-2026)
  21. 1.5.2 Europe Oral Medications for Multiple Sclerosis Sales Breakdown by Type (2021-2026)
  22. 1.5.3 Asia-Pacific Oral Medications for Multiple Sclerosis Sales Breakdown by Type (2021-2026)
  23. 1.5.4 South America Oral Medications for Multiple Sclerosis Sales Breakdown by Type (2021-2026)
  24. 1.5.5 Middle East and Africa Oral Medications for Multiple Sclerosis Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Oral Medications for Multiple Sclerosis Industry Trends
  2. 2.2 Oral Medications for Multiple Sclerosis Industry Drivers
  3. 2.3 Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges
  4. 2.4 Oral Medications for Multiple Sclerosis Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Oral Medications for Multiple Sclerosis Revenue (2021-2026)
  2. 3.2 Global Top Players by Oral Medications for Multiple Sclerosis Sales (2021-2026)
  3. 3.3 Global Top Players by Oral Medications for Multiple Sclerosis Price (2021-2026)
  4. 3.4 Global Oral Medications for Multiple Sclerosis Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Medications for Multiple Sclerosis Major Company Production Sites & Headquarters
  6. 3.6 Global Oral Medications for Multiple Sclerosis Company, Product Type & Application
  7. 3.7 Global Oral Medications for Multiple Sclerosis Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Medications for Multiple Sclerosis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Medications for Multiple Sclerosis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Medications for Multiple Sclerosis Tier 1, Tier 2, and Tier 3
4 Oral Medications for Multiple Sclerosis Regional Status and Outlook
  1. 4.1 Global Oral Medications for Multiple Sclerosis Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Oral Medications for Multiple Sclerosis Historic Market Size by Region
  3. 4.2.1 Global Oral Medications for Multiple Sclerosis Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Oral Medications for Multiple Sclerosis Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Oral Medications for Multiple Sclerosis Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Oral Medications for Multiple Sclerosis Forecasted Market Size by Region
  7. 4.3.1 Global Oral Medications for Multiple Sclerosis Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Oral Medications for Multiple Sclerosis Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Oral Medications for Multiple Sclerosis Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Oral Medications for Multiple Sclerosis by Application
  1. 5.1 Oral Medications for Multiple Sclerosis Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Oral Medications for Multiple Sclerosis Market Size by Application
  6. 5.2.1 Global Oral Medications for Multiple Sclerosis Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Oral Medications for Multiple Sclerosis Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Oral Medications for Multiple Sclerosis Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Oral Medications for Multiple Sclerosis Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Oral Medications for Multiple Sclerosis Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Oral Medications for Multiple Sclerosis Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Oral Medications for Multiple Sclerosis Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Oral Medications for Multiple Sclerosis Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sichuan Omnis Pharmaceutical
  2. 6.1.1 Sichuan Omnis Pharmaceutical Company Information
  3. 6.1.2 Sichuan Omnis Pharmaceutical Business Overview
  4. 6.1.3 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  6. 6.1.5 Sichuan Omnis Pharmaceutical Recent Developments
  7. 6.2 CGeneTech (Suzhou, China)
  8. 6.2.1 CGeneTech (Suzhou, China) Company Information
  9. 6.2.2 CGeneTech (Suzhou, China) Business Overview
  10. 6.2.3 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio
  12. 6.2.5 CGeneTech (Suzhou, China) Recent Developments
  13. 6.3 Qilu Pharmaceutical
  14. 6.3.1 Qilu Pharmaceutical Company Information
  15. 6.3.2 Qilu Pharmaceutical Business Overview
  16. 6.3.3 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  18. 6.3.5 Qilu Pharmaceutical Recent Developments
  19. 6.4 Nanjing Healthnice Pharmaceutical
  20. 6.4.1 Nanjing Healthnice Pharmaceutical Company Information
  21. 6.4.2 Nanjing Healthnice Pharmaceutical Business Overview
  22. 6.4.3 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  24. 6.4.5 Nanjing Healthnice Pharmaceutical Recent Developments
  25. 6.5 HEC Pharm
  26. 6.5.1 HEC Pharm Company Information
  27. 6.5.2 HEC Pharm Business Overview
  28. 6.5.3 HEC Pharm Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio
  30. 6.5.5 HEC Pharm Recent Developments
  31. 6.6 Cisen Pharmaceutical
  32. 6.6.1 Cisen Pharmaceutical Company Information
  33. 6.6.2 Cisen Pharmaceutical Business Overview
  34. 6.6.3 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  36. 6.6.5 Cisen Pharmaceutical Recent Developments
  37. 6.7 Zydus
  38. 6.7.1 Zydus Company Information
  39. 6.7.2 Zydus Business Overview
  40. 6.7.3 Zydus Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Zydus Oral Medications for Multiple Sclerosis Product Portfolio
  42. 6.7.5 Zydus Recent Developments
  43. 6.8 Viatris
  44. 6.8.1 Viatris Company Information
  45. 6.8.2 Viatris Business Overview
  46. 6.8.3 Viatris Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Viatris Oral Medications for Multiple Sclerosis Product Portfolio
  48. 6.8.5 Viatris Recent Developments
  49. 6.9 Teva
  50. 6.9.1 Teva Company Information
  51. 6.9.2 Teva Business Overview
  52. 6.9.3 Teva Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Teva Oral Medications for Multiple Sclerosis Product Portfolio
  54. 6.9.5 Teva Recent Developments
  55. 6.10 Sun Pharmaceuticals
  56. 6.10.1 Sun Pharmaceuticals Company Information
  57. 6.10.2 Sun Pharmaceuticals Business Overview
  58. 6.10.3 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  60. 6.10.5 Sun Pharmaceuticals Recent Developments
  61. 6.11 Sanofi
  62. 6.11.1 Sanofi Company Information
  63. 6.11.2 Sanofi Business Overview
  64. 6.11.3 Sanofi Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Sanofi Oral Medications for Multiple Sclerosis Product Portfolio
  66. 6.11.5 Sanofi Recent Developments
  67. 6.12 Sandoz
  68. 6.12.1 Sandoz Company Information
  69. 6.12.2 Sandoz Business Overview
  70. 6.12.3 Sandoz Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Sandoz Oral Medications for Multiple Sclerosis Product Portfolio
  72. 6.12.5 Sandoz Recent Developments
  73. 6.13 Novartis
  74. 6.13.1 Novartis Company Information
  75. 6.13.2 Novartis Business Overview
  76. 6.13.3 Novartis Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Novartis Oral Medications for Multiple Sclerosis Product Portfolio
  78. 6.13.5 Novartis Recent Developments
  79. 6.14 Mylan
  80. 6.14.1 Mylan Company Information
  81. 6.14.2 Mylan Business Overview
  82. 6.14.3 Mylan Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Mylan Oral Medications for Multiple Sclerosis Product Portfolio
  84. 6.14.5 Mylan Recent Developments
  85. 6.15 Merck
  86. 6.15.1 Merck Company Information
  87. 6.15.2 Merck Business Overview
  88. 6.15.3 Merck Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Merck Oral Medications for Multiple Sclerosis Product Portfolio
  90. 6.15.5 Merck Recent Developments
  91. 6.16 Janssen
  92. 6.16.1 Janssen Company Information
  93. 6.16.2 Janssen Business Overview
  94. 6.16.3 Janssen Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Janssen Oral Medications for Multiple Sclerosis Product Portfolio
  96. 6.16.5 Janssen Recent Developments
  97. 6.17 Glenmark Pharmaceuticals
  98. 6.17.1 Glenmark Pharmaceuticals Company Information
  99. 6.17.2 Glenmark Pharmaceuticals Business Overview
  100. 6.17.3 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  102. 6.17.5 Glenmark Pharmaceuticals Recent Developments
  103. 6.18 Dr. Reddy's Laboratories
  104. 6.18.1 Dr. Reddy's Laboratories Company Information
  105. 6.18.2 Dr. Reddy's Laboratories Business Overview
  106. 6.18.3 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio
  108. 6.18.5 Dr. Reddy's Laboratories Recent Developments
  109. 6.19 Bristol Myers Squibb
  110. 6.19.1 Bristol Myers Squibb Company Information
  111. 6.19.2 Bristol Myers Squibb Business Overview
  112. 6.19.3 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio
  114. 6.19.5 Bristol Myers Squibb Recent Developments
  115. 6.20 Biogen
  116. 6.20.1 Biogen Company Information
  117. 6.20.2 Biogen Business Overview
  118. 6.20.3 Biogen Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Biogen Oral Medications for Multiple Sclerosis Product Portfolio
  120. 6.20.5 Biogen Recent Developments
  121. 6.21 Banner Life Sciences
  122. 6.21.1 Banner Life Sciences Company Information
  123. 6.21.2 Banner Life Sciences Business Overview
  124. 6.21.3 Banner Life Sciences Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio
  126. 6.21.5 Banner Life Sciences Recent Developments
  127. 6.22 Apotex
  128. 6.22.1 Apotex Company Information
  129. 6.22.2 Apotex Business Overview
  130. 6.22.3 Apotex Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Apotex Oral Medications for Multiple Sclerosis Product Portfolio
  132. 6.22.5 Apotex Recent Developments
  133. 6.23 Alembic
  134. 6.23.1 Alembic Company Information
  135. 6.23.2 Alembic Business Overview
  136. 6.23.3 Alembic Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Alembic Oral Medications for Multiple Sclerosis Product Portfolio
  138. 6.23.5 Alembic Recent Developments
  139. 6.24 Accord Healthcare
  140. 6.24.1 Accord Healthcare Company Information
  141. 6.24.2 Accord Healthcare Business Overview
  142. 6.24.3 Accord Healthcare Oral Medications for Multiple Sclerosis Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio
  144. 6.24.5 Accord Healthcare Recent Developments
7 North America by Country
  1. 7.1 North America Oral Medications for Multiple Sclerosis Sales by Country
  2. 7.1.1 North America Oral Medications for Multiple Sclerosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Oral Medications for Multiple Sclerosis Sales by Country (2021-2026)
  4. 7.1.3 North America Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032)
  5. 7.2 North America Oral Medications for Multiple Sclerosis Market Size by Country
  6. 7.2.1 North America Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026)
  8. 7.2.3 North America Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Oral Medications for Multiple Sclerosis Sales by Country
  2. 8.1.1 Europe Oral Medications for Multiple Sclerosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Oral Medications for Multiple Sclerosis Sales by Country (2021-2026)
  4. 8.1.3 Europe Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Oral Medications for Multiple Sclerosis Market Size by Country
  6. 8.2.1 Europe Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026)
  8. 8.2.3 Europe Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Oral Medications for Multiple Sclerosis Sales by Country
  2. 9.1.1 Asia-Pacific Oral Medications for Multiple Sclerosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Oral Medications for Multiple Sclerosis Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Oral Medications for Multiple Sclerosis Market Size by Country
  6. 9.2.1 Asia-Pacific Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Oral Medications for Multiple Sclerosis Sales by Country
  2. 10.1.1 South America Oral Medications for Multiple Sclerosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Oral Medications for Multiple Sclerosis Sales by Country (2021-2026)
  4. 10.1.3 South America Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032)
  5. 10.2 South America Oral Medications for Multiple Sclerosis Market Size by Country
  6. 10.2.1 South America Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026)
  8. 10.2.3 South America Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country
  2. 11.1.1 Middle East and Africa Oral Medications for Multiple Sclerosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Oral Medications for Multiple Sclerosis Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Oral Medications for Multiple Sclerosis Market Size by Country
  6. 11.2.1 Middle East and Africa Oral Medications for Multiple Sclerosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Oral Medications for Multiple Sclerosis Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Oral Medications for Multiple Sclerosis Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Oral Medications for Multiple Sclerosis Value Chain Analysis
  2. 12.1.1 Oral Medications for Multiple Sclerosis Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Oral Medications for Multiple Sclerosis Production Mode & Process
  7. 12.2 Oral Medications for Multiple Sclerosis Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Oral Medications for Multiple Sclerosis Distributors
  10. 12.2.3 Oral Medications for Multiple Sclerosis Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst